Suppr超能文献

相似文献

1
In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery.
J Control Release. 2011 Dec 10;156(2):258-64. doi: 10.1016/j.jconrel.2011.06.036. Epub 2011 Jul 8.
2
Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Int J Nanomedicine. 2017 Jan 27;12:935-947. doi: 10.2147/IJN.S121881. eCollection 2017.
3
Modeling of nanoparticle transport through the female reproductive tract for the treatment of infectious diseases.
Eur J Pharm Biopharm. 2019 May;138:37-47. doi: 10.1016/j.ejpb.2018.09.003. Epub 2018 Sep 7.
5
Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.
J Control Release. 2014 Oct 28;192:202-8. doi: 10.1016/j.jconrel.2014.07.045. Epub 2014 Jul 29.
6
Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.
Biomaterials. 2017 Nov;144:144-154. doi: 10.1016/j.biomaterials.2017.08.029. Epub 2017 Aug 15.
7
Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation.
Acta Biomater. 2014 Nov;10(11):4583-4596. doi: 10.1016/j.actbio.2014.07.015. Epub 2014 Jul 19.
8
Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo.
Nanomedicine (Lond). 2016 Jun;11(11):1337-43. doi: 10.2217/nnm-2016-0047. Epub 2016 May 12.
9
Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation.
Int J Pharm. 2007 Feb 22;331(1):123-32. doi: 10.1016/j.ijpharm.2006.09.015. Epub 2006 Sep 17.
10
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
J Control Release. 2016 Jan 10;221:62-70. doi: 10.1016/j.jconrel.2015.11.003. Epub 2015 Nov 6.

引用本文的文献

3
Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.
Drug Deliv Transl Res. 2023 Dec;13(12):3003-3013. doi: 10.1007/s13346-023-01369-w. Epub 2023 Jun 26.
4
In vitro and ex vivo models for evaluating vaginal drug delivery systems.
Adv Drug Deliv Rev. 2022 Dec;191:114543. doi: 10.1016/j.addr.2022.114543. Epub 2022 Oct 5.
5
Recent Advances in Polymer-Based Vaginal Drug Delivery Systems.
Pharmaceutics. 2021 Jun 15;13(6):884. doi: 10.3390/pharmaceutics13060884.
8
Design of nanomaterials for applications in maternal/fetal medicine.
J Mater Chem B. 2020 Aug 21;8(31):6548-6561. doi: 10.1039/d0tb00612b. Epub 2020 May 26.
9
Enabling sublingual peptide immunization with molecular self-assemblies.
Biomaterials. 2020 May;241:119903. doi: 10.1016/j.biomaterials.2020.119903. Epub 2020 Feb 24.
10
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.
J Control Release. 2020 May 10;321:84-99. doi: 10.1016/j.jconrel.2020.02.006. Epub 2020 Feb 5.

本文引用的文献

1
2
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
4
Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
J Control Release. 2009 Sep 1;138(2):113-21. doi: 10.1016/j.jconrel.2009.05.011. Epub 2009 May 13.
5
Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.
Int J Pharm. 2009 May 21;373(1-2):16-23. doi: 10.1016/j.ijpharm.2009.01.020. Epub 2009 Feb 4.
7
Barrier properties of mucus.
Adv Drug Deliv Rev. 2009 Feb 27;61(2):75-85. doi: 10.1016/j.addr.2008.09.008. Epub 2008 Dec 16.
10
Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine.
Int J Pharm. 2008 Aug 6;360(1-2):164-70. doi: 10.1016/j.ijpharm.2008.04.038. Epub 2008 May 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验